CD19 and Miyoshi myopathy: By using the more precise differentiation of lymphocytes by flow cytometry analysis, we have been able to demonstrate that a count of at least 30 CD19+ B-lymphocytes/μL correlates significantly with a positive SP-AbT and identified the previously suggested threshold of 30 CD19+ B lymphocytes/μL as being predictive for SP-AbT development in patients with MM and other PCD [23].